CEO David J. Bearss, Ph.D., will be participating in a panel discussing the "Landscape of Drug Discovery and Impact of AI Discussion" on Wednesday, May 22, from 1:50 to 2:30 p.m. CEST
Company presentation to unveil new data from HT-4253 in its new clinical Alzheimer's disease program will be held on Thursday, May 23, from 4 to 4:20 p.m. CEST LEHI, Utah, May 14, 2024 /PRNewswire/ -- Halia Therapeutics, a clinical-stage biopharmaceutical company pioneering a novel class of small molecule medications designed to combat inflammation, today announced the unveiling of a new clinical program evaluating its candidate HT-4253 for the treatment of Alzheimer's disease. David J. Bearss, Ph.D., President, and CEO of Halia Therapeutics, will present the scientific rationale and preclinical data for the groundbreaking clinical program HT-4253 in an oral presentation at the Discovery Europe 2024 Conference, taking place May 22 – 23, in Basel, Switzerland. "We are excited to have such a large presence at this year's Discovery Europe 2024 Conference, especially in the programs related to drug discovery to target neurodegenerative disorders," said Dr. Bearss, President, and Chief Executive Officer at Halia Therapeutics. "As part of our participation, we are delighted to unveil and present data on our HT-4253 clinical program, representing a paradigm shift in Alzheimer's disease treatment. By selectively inhibiting LRRK2-mediated regulation of RAB10 function, we aim to address the underlying pathology of Alzheimer's disease and offer hope to combat one of our time's most pressing global health challenges." Details about the presentation are as follows:
Date: May 23, from 4:00 – 4:20 p.m. CEST
Location: Congress Center Basel, MCH Swiss Exhibition (Basil) Ltd. Messe Platz 21, CH-4058 Basel
Additionally, Dr. Bearss will serve as a panelist on the "Landscape of Drug Discovery and Impact of AI" session on May 22, 2023, from 1:50-2:30 p.m. CEST, and as the Chair for Track 4: "Drug Discovery for Neurodegenerative Diseases" session, May 23, 2023, from 9 – 4 p.m. CEST. For more information on the congress please visit: https://oxfordglobal.com/discovery/events/discovery-europe-2024
Halia Therapeutics is unwavering in its commitment to advancing the HT-4253 program through rigorous clinical development. With the ultimate goal of delivering transformative therapies to patients in need, the company eagerly anticipates collaborating with key stakeholders, including patients, caregivers, and the scientific community, to accelerate progress toward a future free from the burden of Alzheimer's disease. The company's headquarters are in Lehi, Utah. For more information, visit www.haliatx.com or follow us on LinkedIn and Twitter (X)
Ignacio Guerrero-Ros, Ph.D.